Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Hematologic Neoplasms 2Colorectal Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomatitis 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Radiodermatitis 1Papillomavirus Infections 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Lung Neoplasms 1Localized Prostate Carcinoma 1Leukemia, Myeloid, Acute 1Hepatitis B 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Endometrial Clear Cell Adenocarcinoma 1Disease Progression 1

Interventions

Cyclophosphamide 34fludarabine 25fludarabine phosphate 24Tacrolimus 24Mycophenolic Acid 23Whole-Body Irradiation 22Busulfan 15Methotrexate 12Melphalan 12Granulocyte Colony-Stimulating Factor 12Antilymphocyte Serum 12thymoglobulin 11Cyclosporine 11Stem Cell Transplantation 10Filgrastim 10Rituximab 9Thiotepa 7Peripheral Blood Stem Cell Transplantation 7Nivolumab 7Dexamethasone 7trametinib 6Radiotherapy 6Mesna 6Cytarabine 6Prednisone 5Calcium Dobesilate 5Bortezomib 5Azacitidine 5Alemtuzumab 5Voriconazole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Hematologic Neoplasms × Practice Guidelines as Topic × Clear all
NCT03125070 2025-01-29

INSPIRE

Fred Hutchinson Cancer Center

Phase 3 Completed
546 enrolled 13 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT04532372 2024-07-03

Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

City of Hope Medical Center

Phase 1/2 Completed
2 enrolled 7 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡